Halozyme Q2 revenue jumps 48%, raises 2026 outlook

Halozyme Therapeutics

06/08/2026 21:11

Overview
U.S. biopharma firm's Q2 revenue rose 48% yr/yr, beating analyst expectations
Adjusted EPS for Q2 beat analyst expectations
Company raised 2026 revenue and EPS guidance, repurchased $333 mln in shares in Q2

Outlook
Halozyme raises 2026 total revenue guidance to $1.835-$1.910 bln, up from $1.710-$1.810 bln
Company now sees 2026 royalty revenue of $1.220-$1.245 bln, up from $1.130-$1.170 bln
2026 non-GAAP diluted EPS forecast raised to $8.65-$9.00 from $7.75-$8.25

Result Drivers
ROYALTY REVENUE GROWTH - Co said 48% yr/yr revenue increase was mainly due to 50% growth in royalty revenue from partner products launched since 2020, including VYVGART Hytrulo by argenx and DARZALEX SC by Janssen
NEW COLLABORATIONS - Co said five new ENHANZE and Hypercon collaboration agreements signed YTD 2026 expanded royalty revenue opportunity
PRODUCT SALES INCREASE - Co said higher product sales contributed to overall revenue growth

Company press release: ID:nPn56fhHGa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$481 mln
$407.49 mln (6 Analysts)
Q2 Adjusted EPS
Beat
$2.28
$1.84 (5 Analysts)
Q2 EPS
 
$1.90
 
Q2 Net Income
 
$229.90 mln
 
Q2 Operating Income
 
$287.70 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Halozyme Therapeutics, Inc. is $91.23, about 9.1% above its August 5 closing price of $83.59
The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 7 three months ago

Reuters Recommended Reads
Aug 5 - Royalty Pharma Q2 adjusted EBITDA beats estimates
Aug 6 - Ligand Pharmaceuticals Q2 revenue rises on royalty growth
Aug 5 - Kymera Therapeutics Q2 collaboration revenue more than doubles, beats estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)